AN2 Therapeutics, Inc.
Načítám obsah…
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.
This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
